drugset
drugset / Trial / NCT04731844

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

NCT04731844 ↗

Phase 2 Completed 30 enrolled University of Rochester
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.

Timeline

Start
2021-12-14
Primary completion
2024-09-19
Completion
2024-09-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Curcumin Small molecule 4 g Oral
Subject Piperine Other / unclassified 5 mg Oral

Indications

monoclonal gammopathy of uncertain significance prostate cancer smoldering plasma cell myeloma